About this Webinar
Liquid biopsy is transforming the landscape of oncology by enabling minimally invasive and non-invasive cancer diagnostics. At the core of this transformation is cell-free DNA (cfDNA), a powerful biomarker found in bodily fluid that provides critical insights into tumor genetics without the need for invasive tissue biopsies. This non-invasive approach not only improves patient comfort and compliance, but also delivers real-time information to guide treatment decisions.
Tailored for oncology researchers and healthcare professionals, this webinar focuses on prostate cancer, one of the most prevalent malignancies, affecting about one in every eight men in the US. We will explore how advancements in cfDNA in cancer research and clinical practice are being harnessed to improve prostate cancer diagnosis and management. Through real-world examples, we'll learn how integrating cfDNA-based liquid biopsies can complement traditional diagnostics, leading to earlier detection and personalized treatment strategies.
About the Speakers
Lohit Khera PhD
Head of Scientific Sales, Norgen Biotek
With more than 10 years of experience in cancer research and molecular biology from prestigious institutions like the Weizmann Institute of Science and LSU Health Science Center, Dr. Khera is dedicated to advancing global cancer research and diagnostics through cutting-edge technologies.
Maggie Xue
Project Manager, Norgen Biotek
Maggie Xue is a Project Manager at Norgen Biotech with a strong educational foundation in biological sciences from the University of Guelph. Maggie is committed to helping healthcare professionals stay informed about the latest advancements in biotechnology. Her work not only supports scientific teams at Norgen Biotek but also extends to broadening public understanding of impactful healthcare innovations.
FAQs
cfDNA (cell-free DNA) is fragmented DNA in the bloodstream. It helps detect genetic mutations in tumors, making it a valuable biomarker for early cancer detection and non-invasive diagnostics.
A liquid biopsy analyzes cfDNA from blood, urine, or plasma, providing real-time insights into tumor genetics without requiring surgical procedures like traditional biopsies.
This webinar is ideal for oncologists, cancer researchers, molecular biologists, college & university students, and healthcare professionals interested in precision oncology and early cancer detection
Yes! The webinar includes a live Q&A session where participants can ask Dr. Lohit Khera & Maggie Xue questions about cfDNA applications in prostate cancer diagnostics